Skip to main content

Advertisement

Table 1 Baseline characteristics of the studies included in meta-analysis

From: Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis

Study Subjects Location Number (TLV/Control) Age LVEF (%) in TLV group/ control group (mean ± SD) Control Mean follow-up TLV dose (mg)/duration (day) Main outcomes
Suzuki 2013 AHF or acute exacerbation of chronic heart failure, NYHA II-IV Japan 54/55 74/75 47 ± 18/44 ± 14 carperitide 14 days 3.75–15 mg/d Symptoms, plasma BNP level, urine volume, adverse events
Suzuki 2014 AHF or acute exacerbation of chronic heart failure, NYHAII-IV Japan 54/55 74/75 47 ± 18/44 ± 14 carperitide 296 days 3.75–15 mg/d Serum sodium and potassium, plasma BNP levels, all-cause deaths
Kimura 2015 ADHF Japan 26/26 80.54/ 86.15 47.54 ± 16.75/ 56.73 ± 11.52 furosemide 7 days 20 mg/d WRF
Matsue 2016 AHF patients with renal dysfunction Japan, America 108/109 72.99/ 72.95 45.4 ± 18.1/ 46.8 ± 16.4 no 2 days 15 mg/d 48-h urine volume, WRF, net fluid loss, change in BNP, change in body weight, in-hospital death
Matsue 2016 AHF patients with renal dysfunction Japan, America 108/109 72.99/ 72.95 45.4 ± 18.1/ 46.8 ± 16.4 no 636 days 15 mg/d All-cause death
Felker 2016 AHF America 129/128 66/63 34 ± 17/32 ± 17 placebo 2 days 30 mg/d Symptomatic endpoints, decongestion and renal endpoints, clinical events
Shanmugam 2016 AHF and concomitant hyponatremia India 25/26 58.9/57 31.9 ± 12.2/ 29.2 ± 8.7 placebo 5 days 15 mg/d Sodium concentration, Likert score, adverse effects
Jujo 2016 AHF Japan 30/30 79/79 NA furosemide 5 days 7.5 mg/d Urine volume, BNP, body weight, WHF
  1. Abbreviations: AHF acute heart failure, NYHA New York Heart Association, BNP brain natriuretic peptide, WRF worsening renal function, WHF worsening heart failure